Drug-Drug Interaction Study of ABP-671 in Gout Patients
This study is looking at how a new drug, ABP-671, interacts with allopurinol, a common medication for gout. If you have gout and are currently taking allopurinol, you might be able to join. The study will measure the levels of allopurinol in your blood at different times to see if ABP-671 changes how your body handles allopurinol. We're looking for about 20 adults, aged 18 to 75, with a diagnosis of gout. The study is open-label, meaning both you and the study team will know which medications you are taking. The goal is to understand how these two drugs work together.
- Study design
- This is an open-label study with about 20 participants. Each participant will receive allopurinol, then allopurinol plus ABP-671, and finally ABP-671 alone, each for 7 days.
- What's involved
- You would take allopurinol for 7 days, then allopurinol plus ABP-671 for 7 days, and then ABP-671 alone for 7 days. Blood samples will be taken at baseline and on specific days throughout the study (Day 1, 7, 8, 14, 15, 21).
- Compensation
- Not stated in the trial record.
- Follow-up
- Blood levels of allopurinol will be measured up to Day 21.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Drug-Drug Interaction Study of ABP-671 in Gout Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Maximum plasma concentration (Cmax) of allopurinolBase line, through Day1, Day 7,Day8,D14,D15,D21
Maximum observed plasma concentration (Cmax) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.
- Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinolBase line, through Day1, Day 7,Day8,D14,D15,D21
Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.